CITF Research Results

CITF Research Results2023-10-27T10:53:53-04:00

Pre-Omicron effectiveness of COVID-19 vaccines against hospitalization and death across Canada

Published in Clinical Infectious Diseases, CITF-funded researchers Drs. Jeff Kwong (University of Toronto), Gaston de Serres (L’Institut national de santé publique du Québec), and Mel Krajden (University of British Columbia), found that two doses of mRNA or viral vector ChAdOx1 (AstraZeneca’s Vaxzevria or COVIDSHIELD) vaccines provided excellent protection against severe outcomes (hospitalization or death) from COVID-19 during the period before the emergence of the Omicron variant.

August 27, 2022|Vaccine surveillance|

Third dose of vaccine enhances antibody response, particularly among older adults

A manuscript from a CITF-funded study in preprint (not yet peer-reviewed) by Drs. Marc Romney (University of British Columbia), Zabrina Brumme and Mark Brockman (Simon Fraser University), demonstrated that a third dose of an mRNA vaccine significantly enhanced the magnitude and durability of antibody responses, including among older adults (>70 years old) who remained COVID-naïve.

August 27, 2022|Vaccine surveillance|

Studying COVID-19 infections in people experiencing homelessness in Toronto

In a paper published in BMJ Open, Dr. Stephan Hwang (MAP Centre for Urban Health Solutions, St. Michael’s Hospital and University of Toronto) and colleagues developed a study protocol documenting the CITF-funded Ku-gaa-gii pimitizi-win study (formerly known as the COVENANT study), which aims to estimate the prevalence and incidence of COVID-19 infection among people experiencing homelessness in Canada.

August 12, 2022|Geographic & priority populations|

High COVID-19 vaccine coverage for people experiencing homelessness in Toronto

A manuscript from a CITF-funded study, published in Vaccines, CITF-funded researcher Dr. Stephen Hwang (MAP Centre for Urban Health Solutions, St. Michael’s Hospital and University of Toronto) and colleagues found that vaccine uptake among people experiencing homelessness in Toronto was high, with 80.4% of the 736 study participants having received at least one dose by summer 2021, and 63.6% having received two or more doses.

August 12, 2022|Geographic & priority populations|

Immune responses to Omicron in Immunocompromised patients

A CITF-funded study published in Nature Communications by Drs. Deepali Kumar and Atul Humar (University Health Network, Toronto), reported that partially and fully vaccinated transplant recipients who were infected with Omicron (the BA.1 variant) have BA.1-specific immune responses comparable to triple vaccinated individuals with normal immune systems.

August 12, 2022|Higher risk due to health conditions|
Go to Top